Medical cannabis for the treatment of insomnia.

Abstract

COI Statement

LBV: no commercial or non‐commercial conflicts of interest relevant to this review. CE: no commercial or non‐commercial conflicts of interest relevant to this review. SD: no commercial or non‐commercial conflicts of interest relevant to this review. LG: no commercial or non‐commercial conflicts of interest relevant to this review

References:

• American Academy of Sleep Medicine. International Classification of Sleep Disorders (ICSD). 3rd edition. American Academy of Sleep Medicine, 2014.
• Morin CM, Benca R. Chronic insomnia. Lancet 2012;379(9821):1129-41.
• Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Medicine Reviews 2002;6(2):97-111.
• Morin CM, Jarrin DC, Ivers H, Merette C, LeBlanc M, Savard J. Incidence, persistence, and remission rates of insomnia over 5 years. JAMA Network Open 2020;3(11):e2018782.
• Walsh JH, Maddison KJ, Rankin T, Murray K, McArdle N, Ree MJ, et al. Treating insomnia symptoms with medicinal cannabis: a randomized, crossover trial of the efficacy of a cannabinoid medicine compared with placebo. Sleep 2021;44(11):zsab149.